99 related articles for article (PubMed ID: 7753547)
41. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein.
Mietz JA; Unger T; Huibregtse JM; Howley PM
EMBO J; 1992 Dec; 11(13):5013-20. PubMed ID: 1464323
[TBL] [Abstract][Full Text] [Related]
42. Specific p53-DNA complexes contain an mdm2-related protein.
Hall AR; Milner J
Oncogene; 1997 Mar; 14(11):1371-6. PubMed ID: 9178897
[TBL] [Abstract][Full Text] [Related]
43. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status.
Graeber TG; Peterson JF; Tsai M; Monica K; Fornace AJ; Giaccia AJ
Mol Cell Biol; 1994 Sep; 14(9):6264-77. PubMed ID: 8065358
[TBL] [Abstract][Full Text] [Related]
44. Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes.
Schon O; Friedler A; Freund S; Fersht AR
J Mol Biol; 2004 Feb; 336(1):197-202. PubMed ID: 14741215
[TBL] [Abstract][Full Text] [Related]
45. p53 alpha-Helix mimetics antagonize p53/MDM2 interaction and activate p53.
Chen L; Yin H; Farooqi B; Sebti S; Hamilton AD; Chen J
Mol Cancer Ther; 2005 Jun; 4(6):1019-25. PubMed ID: 15956260
[TBL] [Abstract][Full Text] [Related]
46. Hdm2 recruits a hypoxia-sensitive corepressor to negatively regulate p53-dependent transcription.
Mirnezami AH; Campbell SJ; Darley M; Primrose JN; Johnson PW; Blaydes JP
Curr Biol; 2003 Jul; 13(14):1234-9. PubMed ID: 12867035
[TBL] [Abstract][Full Text] [Related]
47. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding.
Uhrinova S; Uhrin D; Powers H; Watt K; Zheleva D; Fischer P; McInnes C; Barlow PN
J Mol Biol; 2005 Jul; 350(3):587-98. PubMed ID: 15953616
[TBL] [Abstract][Full Text] [Related]
48. Interaction of oncogenic papillomavirus E6 proteins with fibulin-1.
Du M; Fan X; Hong E; Chen JJ
Biochem Biophys Res Commun; 2002 Aug; 296(4):962-9. PubMed ID: 12200142
[TBL] [Abstract][Full Text] [Related]
49. Conservation of structural domains and biochemical activities of the MDM2 protein from Xenopus laevis.
Marechal V; Elenbaas B; Taneyhill L; Piette J; Mechali M; Nicolas JC; Levine AJ; Moreau J
Oncogene; 1997 Mar; 14(12):1427-33. PubMed ID: 9136986
[TBL] [Abstract][Full Text] [Related]
50. In vitro expressed HPV 8 E6 protein does not bind p53.
Steger G; Pfister H
Arch Virol; 1992; 125(1-4):355-60. PubMed ID: 1642560
[TBL] [Abstract][Full Text] [Related]
51. Protein mutagenesis with monodispersity-based quality probing: selective inactivation of p53 degradation and DNA-binding properties of HPV E6 oncoprotein.
Ristriani T; Nominé Y; Laurent C; Weiss E; Travé G
Protein Expr Purif; 2002 Dec; 26(3):357-67. PubMed ID: 12460759
[TBL] [Abstract][Full Text] [Related]
52. Intrasteric regulation of MDM2.
Shimizu H; Hupp TR
Trends Biochem Sci; 2003 Jul; 28(7):346-9. PubMed ID: 12877998
[No Abstract] [Full Text] [Related]
53. Covalent and noncovalent modifiers of the p53 protein.
Jayaraman L; Prives C
Cell Mol Life Sci; 1999 Jan; 55(1):76-87. PubMed ID: 10065153
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of p53-mediated transactivation by E6 of type 1, but not type 5, 8, or 47, human papillomavirus of cutaneous origin.
Kiyono T; Hiraiwa A; Ishii S; Takahashi T; Ishibashi M
J Virol; 1994 Jul; 68(7):4656-61. PubMed ID: 8207840
[TBL] [Abstract][Full Text] [Related]
55. Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes.
Zauberman A; Barak Y; Ragimov N; Levy N; Oren M
EMBO J; 1993 Jul; 12(7):2799-808. PubMed ID: 8334996
[TBL] [Abstract][Full Text] [Related]
56. iASPP mediates p53 selectivity through a modular mechanism fine-tuning DNA recognition.
Chen S; Wu J; Zhong S; Li Y; Zhang P; Ma J; Ren J; Tan Y; Wang Y; Au KF; Siebold C; Bond GL; Chen Z; Lu M; Jones EY; Lu X
Proc Natl Acad Sci U S A; 2019 Aug; 116(35):17470-17479. PubMed ID: 31395738
[TBL] [Abstract][Full Text] [Related]
57. Regulation of the specific DNA binding function of p53.
Hupp TR; Meek DW; Midgley CA; Lane DP
Cell; 1992 Nov; 71(5):875-86. PubMed ID: 1423635
[TBL] [Abstract][Full Text] [Related]
58. The involvement of E6, p53, p16, MDM2 and Gal-3 in the clinical outcome of patients with cervical cancer.
Stiasny A; Freier CP; Kuhn C; Schulze S; Mayr D; Alexiou C; Janko C; Wiest I; Dannecker C; Jeschke U; Kost BP
Oncol Lett; 2017 Oct; 14(4):4467-4476. PubMed ID: 29085443
[TBL] [Abstract][Full Text] [Related]
59. Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants.
Halazonetis TD; Kandil AN
EMBO J; 1993 Dec; 12(13):5057-64. PubMed ID: 8262048
[TBL] [Abstract][Full Text] [Related]
60. Cloning, sequence analysis and expression of the cDNAs encoding the canine and equine homologues of the mouse double minute 2 (mdm2) proto-oncogene.
Nasir L; Burr PD; McFarlane ST; Gault E; Thompson H; Argyle DJ
Cancer Lett; 2000 Apr; 152(1):9-13. PubMed ID: 10754200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
